4basebio PLC (AIM:4BB)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 530.00
0.00 (0.00%)
Nov 4, 2026, 8:00 AM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 82.35 million as of November 4, 2026. It is the 24,656th most valuable company in the world and the 553rd biggest in the United Kingdom. Its market cap has decreased by 32.22% in one year.
Market Cap
82.35M
Enterprise Value
91.41M
Revenue
781.00K
Global Rank
Country Rank
#553 United Kingdom
PE Ratio
n/a
ChartMarket Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 82.35M, an increase of 98.10%. That is a compound annual growth rate of 12.71%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 4, 2026 | 82.35M | -13.48% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Avacta Group | 279.64M |
| Bioventix | 107.37M |
| Scancell Holdings | 104.86M |
| Faron Pharmaceuticals Oy | 62.99M |
| Ondine Biomedical | 52.19M |
| Poolbeg Pharma | 48.22M |
| Hemogenyx Pharmaceuticals | 42.30M |
| Arecor Therapeutics | 37.37M |